Zoledronic Acid Slows Bone Loss, Also Stops New Bone Formation
The commonly used osteoporosis drug zoledronic acid slows bone loss in postmenopausal osteoporosis patients, but it also boosts levels of a biomarker that inhibits bone formation, according to a study recently published online edition in the Journal of Clinical Endocrinology & Metabolism
Source: AAFP Health of the Public - Category: Primary Care Source Type: news
More News: American Academy of Family Physicians (AAFP) | Endocrinology | Health | Orthopaedics | Osteoporosis | Primary Care | Reclast | Study | Zometa